Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment
| Autor: | Pierre Tiberghien, C. Faucher, Agnes Buzyn, M. Robin, Bruno Lioure, Etienne Daguindau, Eric Deconinck, M Kuentz |
|---|---|
| Přispěvatelé: | Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service greffe de moelle osseuse, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Unité de Transplantation et de Thérapie Cellulaire, Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Saas, Philippe, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -hopital Jean Minjoz, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ) |
| Rok vydání: | 2009 |
| Předmět: |
MESH: Tissue Donors
medicine.medical_treatment MESH : Child Preschool Immunotherapy Adoptive Anti tumour 0302 clinical medicine immune system diseases hemic and lymphatic diseases [ SDV.IMM ] Life Sciences [q-bio]/Immunology Medicine MESH : Graft Survival MESH : Tissue Donors MESH: Middle Aged Hematology Graft Survival Hematopoietic Stem Cell Transplantation MESH : Adult Middle Aged Tissue Donors 3. Good health Haematopoiesis surgical procedures operative 030220 oncology & carcinogenesis Child Preschool Hematologic Neoplasms MESH: Immunotherapy Adoptive [SDV.IMM]Life Sciences [q-bio]/Immunology Stem cell MESH : Hematologic Neoplasms MESH: Transplantation Chimera Adult medicine.medical_specialty Graft failure [SDV.IMM] Life Sciences [q-bio]/Immunology MESH: Graft Survival MESH : Transplantation Homologous Graft vs Leukemia Effect 03 medical and health sciences MESH : Hematopoietic Stem Cell Transplantation Internal medicine MESH: Transplantation Homologous Humans Transplantation Homologous MESH : Middle Aged MESH: Hematopoietic Stem Cell Transplantation Transplantation Transplantation Chimera MESH: Humans Hematopoietic cell business.industry MESH : Transplantation Chimera MESH : Humans MESH: Child Preschool MESH : Graft vs Leukemia Effect MESH: Adult Immunotherapy MESH: Graft vs Leukemia Effect Immunology business human activities MESH : Immunotherapy Adoptive MESH: Hematologic Neoplasms 030215 immunology |
| Zdroj: | Bone Marrow Transplantation Bone Marrow Transplantation, Nature Publishing Group, 2010, 45 (1), pp.177-80. ⟨10.1038/bmt.2009.96⟩ Bone Marrow Transplantation, Nature Publishing Group, 2010, 45 (1), pp.177-80. 〈10.1038/bmt.2009.96〉 |
| ISSN: | 1476-5365 0268-3369 |
| DOI: | 10.1038/bmt.2009.96⟩ |
| Popis: | International audience; Remissions of haematological malignancies have been reported after allo-SCT, despite donor cell rejection, suggesting that sustained allogeneic engraftment is not mandatory to obtain a lasting anti-tumour effect. To evaluate the potential benefit from transient post-allo-SCT alloreactivity, we took advantage of the Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC) registry to colligate 14 patients with an efficient and long-lasting allogeneic (GVL) effect after allo-SCT for haematological malignancies, despite transient or absent engraftment. None received a second allogeneic graft after autologous recovery. The median duration of remission after autologous reconstitution was 118 (12-252) months. Although we cannot exclude the possibility that some patients were cured before allo-SCT, this retrospective analysis does strongly suggest that an efficient GVL effect can be observed without sustained donor engraftment, and that the transient presence of donor T cells might be sufficient to induce a powerful GVL effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|